Potassium Binders

Agnieszka Tycinska, Ewa Jankowska


No abstract


Heart Failure; Potassium binders

Full Text:



Llubani R, Vukadinović D, Werner C et al. Hyperkalaemia in Heart Failure-Pathophysiology, Implications and Therapeutic Perspectives. Curr Heart Fail Rep 2018;15(6):390-397.

Cardiovascular diseases-fact sheet. World Health Organization. http://www.who.int/ mediacentre/factsheets/fs317/en/.

Ponikowski P, Voors AA, Anker S et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Eur Heart J 2016; 37(27):2129-2200.

Acker CG, Johnson JP, Palevsky PM, Greenberg A. Hyperkalemia in hospitalized patients. Causes, adequacy of treatment and results of an attempt to improve physician compliance with published therapy guidelines. Arch Intern Med 1998; 158(8):917-24.

Fleet JL, Shariff SZ, Gandhi S, Weir MA, Jain AK, Garg AX. Validity of the International Classification of Diseases 10th revision code for hyperkalaemia in elderly patients at presentation to an emergency department and at hospital admission. BMJ Open. 2012; 2(6): pii: e002011.

Einhorn LM, Zhan M, Hsu VD, et al. The frequency of hyperkalemia and its significanc in chronic kidney disease. Arch Intern Med 2009; 169(12):1156-62.

Drawz PE, Babineau DC, Rahman M. Metabolic complications in elderly adults with chronic kidney disease. J Am Geriatr Soc 2012; 60(2):310-5.

Kovesdy CP. Updates in hyperkalemia: Outcomes and therapeutic strategies. Rev Endocr Metab Disord 2017;18(1):41-47.

Weir MR, Rolfe M. Potassium homeostasis and renin-angiotensin-aldosterone system inhibitors. Clin J Am Soc Nephrol. 2010; 5:531-548.

Susantitaphong P, Sewaralthahab K, Balk EM, et al. Efficacy and safety of combined vs. single renin-angiotensin-aldosterone system blockade in chronic kidney disease: a meta-analysis. Am J Hypertens. 2013; 26:424-441.

Desai A. Hyperkalaemia associated with inhibitors of the renin-angiotensin aldosterone system: balancing risk and benefit. Circulation 2008;118(16):16 9-11.

Palmer BF. Managing hyperkalemia caused by inhibitors of the renin angiotensin- aldosterone system. N Engl J Med 2004; 351:585-92.

Khder Y, Shi V, McMurray JV, Lefkowitz MP. Sacubitril/Valsartan (LCZ696) in Heart Failure. Hand Exp Pharmacol 2017; 243:133-165.

Palmer BF, Clegg DJ. Diagnosis and treatment of hyperkalemia. Cleve Clin J Med 2017;84(12):934-942.

Fordjour KN, Walton T, Doran JJ. Management of hyperkalemia in hospitalized patients. Am J Med Sci 2014; 347(2):93-100.

Emmett M, Hootkins RE, Fine KD, Santa Ana CA, Porter JL, Fordtran JS. Effect of three laxatives and a cation exchange resin on fecal sodium and potassium excretion. Gastroenterology 1995; 108(3):752-60.

Scherr L, Ogden DA, Mead AW, Spritz N, Rubin AL. Management of hyperkalemia with a cation-exchange resin. N Engl J Med 1961; 264:115-9.

Harel Z, Harel S, Shah PS, et al. Gastrointestinal adverse events with sodium polystyrene sulfonate (kayexalate) use: a systematic review. Am J Med 2013; 126(3):264.e9-24.

Nepal M, Bucaloiu ID, Norfolk ER. Hypernatremia in a patient treated with sodium polystyrene sulfonate. Int J Nephrol Renovasc Dis 2010; 3:141-3.

Kosiborod M, Rasmussen HS, Lavin P, et al. Effect of sodium zirconium cyclosilicate on potassium lowering for 28 days among outpatients with hyperkalemia: the HARMONIZE randomized clinical trial. JAMA 2014; 312(21):2223-33.

Anker SD, Kosiborod M, Zannad F et al. Maintenance of serum potassium with sodium zirconium cyclosilicate (ZS-9) in heart failure patients: results from a phase 3 randomized, double-blind, placebo-controlled trial. Eur J Heart Fail 2015;17(10):1050- 1056.

Pitt B, Bakris GL, Bushinsky DA, et al. Effect of patiromer on reducing serum potassium and preventing recurrent hyperkalaemia in patients with heart failure and chronic kidney disease on RAAS inhibitors. Eur J Heart Fail 2015; 17(10):1057-65.

Pitt B, Anker SD, Bushinsky DA, et al. Evaluation of the efficacy and safety of RLY5016, a polymeric potassium binder, in a double-blind, placebo-controlled study in patients with chronic heart failure (the PEARL-HF trial). Eur Heart J 2011; 32(7):820-8.

Buysee JM, Huang IZ, Pitt B. PEARL-HF: prevention of hyperkalemia in patients with heart failure using a novel polymeric potassium binder, RLY5016. Future Cardiol 2012; 8(1):17-28.

Weir MR, Bakris GL, Bushinsky DA, et al.; OPAK-HK Investigators. Patiromer in patients with kidney disease and hyperkalemia receiving RAAS inhibitors. N Engl J Med 2015; 372(3):211-221.

Pitt B, Bakris GL, Weir MR, et al. Long-term effects of patiromer for hyperkalaemia treatment in patients with mild heart failure and diabetic nephropathy on angiotensin- converting enzymes/angiotensin receptor blockers: results from AMETHYST-DN. ESC Heart Fail 2018; 5(4):592-602.

Rosano GMC, Tamargo J, Kjeldsen KP et al (2018). Expert consensus document on the management of hyperkalaemia in patients with cardiovascular disease treated with renin angiotensin aldosterone system inhibitors: coordinated by the Working Group on Cardiovascular Pharmacotherapy of the European Society of Cardiology. Eur Heart J Cardiovasc Pharmacother 4: 180-8.

Shewan LG, Coats AJS, Henein MY. Authors’ Responsibilities and Ethical Publishing. International Cardiovascular Forum Journal 2018;13:3-4, DOI: 10.17987/icfj.v13i0.525

DOI: https://doi.org/10.17987/icfj.v18i0.621

Copyright (c) 2019 Ewa Jankowska, Agnieszka Tycinska

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.